Digoxin 0.05mg; per mL; lime-flavored; contains alcohol 10%.
Your search for digoxin returned 60 results
However, compared with patients not on digoxin, patients with a serum digoxin concentration ≥1.2 ng/mL had a 56% increased hazard of mortality (adjusted HR, 1.56; 95% confidence interval, 1.2 to 2.04). For each 0.5-ng/mL increase (P=0.001), there was a 19% higher adjusted hazard for death, and these results were similar in patients with and without heart failure.
About one in five patients with non-valvular atrial fibrillation (NVAF) receives digoxin, with the indication for use considered inappropriate in nearly 60%, according to a study published in the Journal of Clinical Pharmacy and Therapeutics.
A recent review on the role of digoxin in atrial fibrillation (AF) has concluded that clinicians should avoid using digoxin monotherapy for rate control in patients with AF when other options are available.
Only one-in-five with heart failure with reduced ejection fraction receive digoxin at discharge
A calculator for determining Digoxin Dosing.
Previous research has yielded conflicting evidence on the use of digoxin in patient with atrial fibrillation (AF) or congestive heart failure (CHF), but the largest systematic review and meta-analysis suggests that there is an increased risk of all-cause mortality with digoxin use in these patients.
The use of digoxin in atrial fibrillation has remained controversial because of its narrow therapeutic window and its possible contribution to ventricular tachyarrhythmias and severe bradyarrhythmias.
New findings suggest that digoxin use carries an increased risk of death and hospitalization in adults with incident atrial fibrillation AF) and no heart failure.
Among patients with newly diagnosed atrial fibrillation (AF), the use of digoxin is associated with increased risk of death.